Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

被引:127
|
作者
Thiele, Juergen [1 ]
Kvasnicka, Hans Michael [1 ]
Muellauer, Leonhard [2 ]
Buxhofer-Ausch, Veronika [3 ]
Gisslinger, Bettina [3 ]
Gisslinger, Heinz [3 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Med Univ Vienna, Inst Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; WORLD-HEALTH-ORGANIZATION; BONE-MARROW BIOPSY; CHRONIC MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA-VERA; DIAGNOSTIC-CRITERIA; INTEROBSERVER RELIABILITY; DIFFERENTIAL-DIAGNOSIS; PROGNOSTIC-FACTORS; NEOPLASMS;
D O I
10.1182/blood-2010-07-293761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofibrosis (PMF) presenting with thrombocythemia. To investigate the impact and reproducibility of bone marrow (BM) morphology according to the World Health Organization classification, 295 patients with the presumptive clinical diagnosis of either ET or early PMF were studied. Data of this cohort (Vienna group) were compared with 732 corresponding patients (Cologne group). Evaluating blindly (only age and gender known) BM specimens, the 2 groups of pathologists achieved an overall consensus of 78% regarding the total series and 88% concerning the discrimination between ET versus PMF. In 126 ET and 81 early PMF patients without pretreatment and complete documentation, a 90% concordance with the independently established clinical diagnosis was found. In 12 patients, overlapping of histopathology and some clinical findings between ET and polycythemia vera occurred. Contrasting ET, early PMF showed significant differences of presenting hematologic data and an unfavorable prognosis (estimated mean survival, 14 vs 21 years). Comparison of clinical and survival data of the Vienna cohort with the historical Cologne series revealed an overall congruence. This study highlights the impact of BM morphology for the differentiation between true vs false ET. (Blood. 2011; 117(21): 5710-5718)
引用
收藏
页码:5710 / 5718
页数:9
相关论文
共 50 条
  • [41] The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis
    Ponce, Cesar Cilento
    Chauffaille, Maria de Lourdes F.
    Ihara, Silvia Saiuli M.
    Silva, Maria Regina R.
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2337 - 2344
  • [42] Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
    Buxhofer-Ausch, Veronika
    Gisslinger, Heinz
    Thiele, Juergen
    Gisslinger, Bettina
    Kvasnicka, Hans-Michael
    Muellauer, Leonhard
    Frantal, Sophie
    Carobbio, Alessandra
    Passamonti, Francesco
    Rumi, Elisa
    Ruggeri, Marco
    Rodeghiero, Francesco
    Randi, Maria L.
    Bertozzi, Irene
    Vannucchi, Alessandro M.
    Antonioli, Elisabetta
    Finazzi, Guido
    Gangat, Naseema
    Tefferi, Ayalew
    Barbui, Tiziano
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (07) : 669 - 672
  • [43] Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis
    Thiele, J
    Kvasnicka, HM
    Zankovich, R
    Diehl, V
    HAEMATOLOGICA, 2000, 85 (11) : 1126 - 1134
  • [44] Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis
    Aumann, K.
    Frey, A. -V.
    May, A. M.
    Hauschke, D.
    Kreutz, C.
    Marx, J. P.
    Timmer, J.
    Werner, M.
    Pahl, H. L.
    PATHOLOGE, 2013, 34 : 201 - 209
  • [45] Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
    Mora, Barbara
    Rumi, Elisa
    Guglielmelli, Paola
    Barraco, Daniela
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Cazzola, Mario
    Vannucchi, Alessandro Maria
    Giorgino, Toni
    Passamonti, Francesco
    CANCER MEDICINE, 2019, 8 (09): : 4089 - 4092
  • [46] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Newberry, Kate J.
    Manshouri, Taghi
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
  • [47] Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea
    Lee, Ho Sup
    Park, Lee Chun
    Lee, Eun Mi
    Lee, Shin Jun
    Shin, Seong Hoon
    Im, Hana
    Do, Kil Min
    Kim, Eeon Jin
    Ye, Byeong Jin
    Song, Moo Kon
    Kim, Sung-Hyun
    Lee, Sang Min
    Lee, Won Sik
    Kim, Yang Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (01) : 70 - 75
  • [48] Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
    Agarwal, M. B.
    Malhotra, Hemant
    Chakrabarti, Prantar
    Varma, Neelam
    Mathews, Vikram
    Bhattacharyya, Jina
    Seth, Tulika
    Gayathri, K.
    Menon, Hari
    Subramanian, P. G.
    Sharma, Ajay
    Bhattacharyya, Maitreyee
    Mehta, Jay
    Vaid, A. K.
    Shah, Sandeep
    Aggarwal, Shyam
    Gogoi, P. K.
    Nair, Reena
    Agarwal, Usha
    Varma, Subhash
    Prasad, S. V. S. S.
    Manipadam, Marie Therese
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2015, 36 (01) : 3 - 16
  • [49] Different CALR mutation subtypes in essential thrombocythemia and primary myelofibrosis patients without JAK2 mutation
    Saleh, Layla M.
    Algamal, Reem
    Abd Elmasseh, Hanaa
    Barber, Emily
    Abdel-ghaffar, Hasan
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (02) : 235 - 243
  • [50] National clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018)
    Melikyan, A. L.
    Kovrigina, A. M.
    Subortseva, I. N.
    Shuvaev, V. A.
    Afanasiev, B., V
    Ageeva, T. A.
    Baikov, V. V.
    Vinogradova, O. Yu
    Golenkov, A. K.
    Gritsaev, S., V
    Zaritskiy, A. Yu
    Kaplanov, K. D.
    Lomaia, E. G.
    Martynkevich, I. S.
    Morozova, E., V
    Pospelova, T., I
    Sokolova, M. A.
    Sudarikov, A. B.
    Turkina, A. G.
    Shatokhin, Yu, V
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 63 (03): : 275 - 315